Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-β Peptide Injection in Rats

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zussy, Charleine ^a,b,c   Brureau, Anthony ^a,b,c   Keller, Emeline ^a,b,c   Marchal, Stéphane ^a,b,c   Blayo, Claire ^a,b,c   Delair, Brice ^a,b,c   Ixart, Guy ^a,b,c   Maurice, Tangui ^a,b,c   Givalois, Laurent ^a,b,c  

^a University of Montpellier   (France)

^b UNIV MONTPELLIER   (France)

^c PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 12; CASPASE 3; CASPASE 9; CELL PROTEIN; CORTICOSTERONE; GLIAL FIBRILLARY ACIDIC PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN IBA1; TAU PROTEIN; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BODY TEMPERATURE; CELL ACTIVATION; CELL LOSS; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; HIPPOCAMPUS; HISTOPATHOLOGY; IN VIVO STUDY; LIPID PEROXIDATION; LONG TERM MEMORY; MACROGLIA; MALE; MEMORY DISORDER; MICROGLIA; MITOCHONDRION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SHORT TERM MEMORY; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BODY WEIGHT; BRAIN; CORTICOSTERONE; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INFUSIONS, INTRAVENTRICULAR; LIPID PEROXIDATION; MALE; MEMORY; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS;

RATTUS;

EID: 84871747365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053117     Document Type: Article

References (87)

1. Mattson MP, (2004) Pathways towards and away from Alzheimer's disease. Nature 430: 631-639.
2. Selkoe DJ, (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81: 741-766.
3. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
4. Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, et al. (2005) Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease. Neurol Res 27: 869-881.
5. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97-100.
6. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
7. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, et al. (2005) Amyloid-β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556-561.
8. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ(1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.
9. Ferreira ST, Vieira MN, De Felice FG, (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345.
10. Walsh DM, Selkoe DJ, (2007) Aβ oligomers- A decade of discovery. J Neurochem 101: 1172-1184.
11. Glenner GG, Wong CW, (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.
12. Russo C, Schettini G, Saido TC, Hulette C, Lippa C, et al. (2000) Presenilin-1 mutations in Alzheimer's disease. Nature 405: 531-532.
13. Tekirian TL, (2001) Commentary: Aβ N-terminal isoforms: Critical contributors in the course of Alzheimer's disease pathophysiology. J Alzheimers Dis 3: 241-248.
14. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, et al. (2007) Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25-35) oligomers, S100b and neurotransmitters. J Neuroimmunol 186: 181-192.
15. Kaneko I, Morimoto K, Kubo T, (2001) Drastic neuronal loss in vivo by β-amyloid racemized at Ser(26) residue: Conversion of non-toxic [D-Ser(26)]Aβ 1-40 to toxic and proteinase-resistant fragments. Neuroscience 104: 1003-1011.
16. Kubo T, Nishimura S, Kumagae Y, Kaneko I, (2002) In vivo conversion of racemized β-amyloid ([D-Ser 26]Aβ 1-40) to truncated and toxic fragments ([D-Ser 26] Aβ 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70: 474-483.
17. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW, (1993) Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 13: 1676-1687.
18. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, et al. (1995) Structure-activity analyses of β-amyloid peptides: Contributions of the β 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265.
19. Yankner BA, Duffy LK, Kirschner DA, (1990) Neurotrophic and neurotoxic effects of amyloid-β protein: Reversal by tachykinin neuropeptides. Science 250: 279-282.
20. Zussy C, Brureau A, Delair B, Marchal S, Keller E, et al. (2011) Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid-β fragment in rats. Amer J Pathol 179: 315-334.
21. Yamada K, Nabeshima T, (2000) Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 88: 93-113.
22. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA, (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J Am Chem Soc 123: 5625-5631.
23. Arancibia S, Silhol M, Moulière F, Meffre J, Höllinger I, et al. (2008) Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31: 316-326.
24. Alkam T, Nitta A, Mizoguchi H, Itoh A, Murai R, et al. (2008) The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid-β in mice. J Pharmacol Exp Ther 327: 137-147.
25. Delobette S, Privat A, Maurice T, (1997) In vitro aggregation facilities β-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol 319: 1-4.
26. Maurice T, Lockhart BP, Privat A, (1996) Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
27. Maurice T, Lockhart BP, Su TP, Privat A, (1996) Reversion of β-25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Res 731: 249-253.
28. Meunier J, Ieni J, Maurice T, (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid-β (25-35) peptide-induced toxicity in mice involve an interaction with the sigma(1) receptor. Br J Pharmacol 149: 998-1012.
29. Stepanichev MY, Zdobnova IM, Yakovlev AA, Onufriev MV, Lazareva NA, et al. (2003) Effects of Tumor necrosis factor-alpha central administration on hippocampal damage in rat induced by amyloid β-peptide (25-35). J Neurosci Res 71: 110-120.
30. Villard V, Espallergues J, Keller E, Alkam T, Nitta A, et al. (2009) Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative Anavex1-41 against amyloid-β25-35-induced toxicity in mice. Neuropsychopharmacology 34: 1552-1566.
31. Yamaguchi Y, Kawashima S, (2001) Effects of amyloid-β (25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 412: 265-272.
32. Klementiev B Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, et al. (2007) A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ(25-35). Neuroscience 145: 209-224.
33. Chavant F, Deguil J, Pain S, Ingrand I, Milin S, et al. (2009) Imipramine, in part through tumor necrosis factor inhibition, prevents cognitive decline and-amyloid accumulation in a mouse model of Alzheimer's Disease. J Pharmacol Exp Ther 332: 505-514.
34. Stepanichev MY, Moiseeva YV, Lazareva NA, Onufriev MV, Gulyaeva NV, (2003) Single intracerebroventricular administration of amyloid-β(25-35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Res Bull 61: 197-205.
35. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. 3rd ed., Academic Press, San Diego.
36. Meunier J, Gue M, Recasens M, Maurice T, (2004) Attenuation by a sigma1 receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats. Br J Pharmacol 142: 689-700.
37. Givalois L, Naert G, Rage F, Ixart G, Arancibia S, et al. (2004) A single brain-derived neurotrophic factor injection modifies hypothalamo-pituitary-adrenocortical axis activity in adult male rats. Mol Cell Neurosci 27: 280-295.
38. Hermes-Lima M, Willmore WG, Storey KB, (1995) Quantification of lipid peroxidation in tissue extracts based on fe(iii)xylenol orange complex formation. Free Radic Biol Med 19: 271-280.
39. Cotrufo T, Viegi A, Berardi N, Bozzi Y, Mascia L, et al. (2003) Effects of neurotrophins on synaptic protein expression in the visual cortex of dark-reared rats. J Neurosci 23: 3566-3571.
40. Givalois L, Arancibia S, Alonso G, Tapia-Arancibia L, (2004) Expression of BDNF and its receptors in the median eminence cells with sensitivity to stress. Endocrinology 135: 4737-4747.
41. Naert G, Ixart G, Tapia-Arancibia L, Givalois L, (2006) Continuous icv infusion of brain-derived neurotrophic factor modifies hypothalamic-pituitary-adrenal axis activity, locomotor activity and body temperature rhythms in adult male rats. Neuroscience 139: 779-789.
42. Stepanichev MY, Zdobnova IM, Zarubenko II, Lazareva NA, Gulyaeva NV, (2006) Studies of the effects of central administration of β-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36: 101-106.
43. Stepanichev MY, Zdobnova IM, Zarubenko II, Moiseeva YV, Lazareva NA, et al. (2004) Amyloid-β(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol Behav 80: 647-655.
44. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, et al. (2005) The role of cell-derived oligomers of Aβ in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33: 1087-1090.
45. Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttila T, (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis 20: 858-870.
46. McGeer PL, Itagaki S, Tago H, McGeer EG, (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79: 195-200.
47. Rogers J, Luber-Narod J, Styren SD, Civin WH, (1988) The inflammatory response in Alzheimer's disease. Neurobiol Aging 9: 339-349.
48. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC, (1989) Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the lfa-1 family. Neurosci Lett 101: 288-292.
49. Vanzani MC, Iacono RF, Caccuri RL, Berria MI, (2005) Immunochemical and morphometric features of astrocyte reactivity vs. plaque location in Alzheimer's disease. Medicina (B. Aires) 65: 213-218.
50. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJM, van Gool WA, et al. (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J Neur Trans 113: 1685-1695.
51. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663-674.
52. Rogers J, (2008) The inflammatory response in Alzheimer's disease. J Periodontol 79: 1535-1543.
53. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB, (2008) Neuroinflammation: Implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39: 1-16.
54. Blennow K, de Leon MJ, Zetterberg H, (2006) Alzheimer's disease. Lancet 368: 387-403.
55. Jakob-Roetne R, Jacobsen H, (2009) Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl 48: 3030-3059.
56. Abraham I, Harkany T, Horvath KM, Veenema AH, Penke B, et al. (2000) Chronic corticosterone administration dose-dependently modulates Aβ(1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol 12: 486-494.
57. Von Bohlen Und Halbach O, (2007) Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res 329: 409-420.
58. Li X, Zuo P, (2005) Effects of Aβ(25-35) on neurogenesis in the adult mouse subventricular zone and dentate gyrus. Neurol Res 27: 218-222.
59. Krugers HJ, Koolhaas JM, Bohus B, Korf J, (1993) A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. Neurosci Lett 154: 73-77.
60. Lowy MT, Gault L, Yamamoto BK, (1993) Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentration in the hippocampus. J Neurochem 61: 1957-1960.
61. McEwen BS, (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 583: 174-185.
62. Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, et al. (2007) The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry 14: 95-105.
63. Goodman Y, Bruce AJ, Cheng B, Mattson MP, (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 66: 1836-1844.
64. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, et al. (1986) Cortisol and Alzheimer's disease, I: Basal studies. Am J Psy 143: 300-305.
65. Masugi F, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, et al. (1989) High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type. Methods Find Exp Clin Pharmacol 11: 707-710.
66. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC, (2003) Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22: 8608-8618.
67. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y, (2002) An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 277: 34287-34294.
68. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, et al. (2002) Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 277: 21836-21842.
69. Pop C, Salvesen GS, (2009) Human caspases: Activation, specificity, and regulation. J Biol Chem 284: 21777-21781.
70. Sutton ET, Hellermann GR, Thomas T, (1997) β-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp Cell Res 230: 368-376.
71. Geci C, How J, Alturaihi H, Kumar U, (2007) β-amyloid increases somatostatin expression in cultured cortical neurons. J Neurochem 101: 664-673.
72. Bazan-Peregrino M, Gutierrez-Kobeh L, Moran J, (2007) Role of brain-derived neurotrophic factor in the protective action of N-methyl-D-aspartate in the apoptotic death of cerebellar granule neurons induced by low potassium. J Neurosci Res 85: 332-341.
73. Nguyen N, Lee SB, Lee YS, Lee KH, Ahn JY, (2009) Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and MAPK pathways. Neurochem Res 34: 942-951.
74. Wang R, Li YB, Li YH, Xu Y, Wu HL, et al. (2008) Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 1210: 84-91.
75. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
76. Khan A, Vaibhav K, Javed H, Khan MM, Tabassum R, et al. (2012) Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 369: 55-65.
77. Lin F, Xie B, Cai F, Wu G, (2012) Protective effect of Puerarin on β-amyloid-induced neurotoxicity in rat hippocampal neurons. Arzneimittelforschung 62: 187-193.
78. Thal DR, Rub UM, Orantes MM, Braak HM, (2002) Phases of Aβ-deposition in the human brain and its relevance for the development of Alzheimer's disease. Neurology 58: 1791-1800.
79. Van de Nes J, Konermann S, Nafe R, Swaab D, (2006) β-protein/a4 deposits are not associated with hyperphosphorylated Tau in somatostatin neurons in the hypothalamus of Alzheimer's disease patients. Acta Neuropathol 111: 126-138.
80. Van de Nes JA, Kamphorst W, Ravid R, Swaab DF, (1998) Comparison of β-protein/a4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: Amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol 96: 129-138.
81. Standaert DG, Lee VM, Greenberg BD, Lowery DE, Trojanowski JQ, (1991) Molecular features of hypothalamic plaques in Alzheimer's disease. Am J Pathol 139: 681-691.
82. Lin HB, Yang XM, Li TJ, Cheng YF, Zhang HT, et al. (2009) Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease. Psychopharmacol 204: 705-714.
83. Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA, (1997) Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 18: 591-608.
84. Schindowski K, Bretteville A, Leroy K, Bégard S, Brion JP, et al. (2006) Alzheimer's disease-like Tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Amer J Pathol 169: 599-616.
85. Bertrand J, Plouffe V, Sénéchal P, Leclerc N, (2010) The pattern of human Tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. Neuroscience 168: 323-334.
86. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884.
87. Millucci L, Ghezzi L, Bernardini G, Santucci A, (2010) Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sc 11: 54-67.